Beyond these observations in mouse models of BC, Hinz et al. have shown that AKT3 activity is elevated in human bone metastatic MDA-MB-231 cells, and AKT3 may decrease the metastatic potential of these bone-seeking BC cells via the activation of HER2 and discoidin domain receptor (DDR) kinases, and the downregulation of TGFβ [50]. This evidence concerns the gene AKT3 and breast cancer.